The effect of applying brain-orientated neonatal intensive care for term infants with severe neonatal asphyxia was studied. Such treatment included protective phenobarbitone administration together with assisted ventilation and other measures to counteract postasphyxial cerebral oedema and any abrupt changes in blood pressure and oxygenation. The mortality rate and incidence of long-term sequelae were reduced appreciably, resulting in a 0-1 year mortality rate of 14% (previously 50%) and an incidence of neurodevelopmental handicap at 18 months of 17 % (previously 50%). It is important in the management of infants with severe asphyxia at birth to avoid blood pressure fluctuations and to control neuronal epileptic activity by the use of barbiturates and early ventilator treatment.
Some reports have shown that the long-term prog--w Material and methods nosis of infants who respond rapidly to resuscitation after neonatal asphyxia may not be as bad as might We studied 35 term have been expected from the initial condition of the newborn infants witl baby and the course of the disease. However, the treated in our neonat more severely asphyxiated infant with inadequate the 6-year period 197 respiration and abnormal motor activity after years (May 1973 to Oc resuscitation eventually develops apnoeic spells and A) were treated co convulsions, and such infants have a high mortality During the second 3 rate and incidence of cerebral handicaps. Conse-October 1979) 19 infal quently in any baby with severe asphyxia the risk of accordance with our s serious handicap is high. As The aim of our study was to evaluate the advant-had had signs of int ages of early administration of phenobarbitone in abnormal fetal heart high dosage combined with vigorous treatment of graphic registration a shock and ventilatory support in term infants with 7 20 Electroencephalograms were recorded in all infants. In any infant with convulsions, a lumbar puncture to search for signs of meningitis or cerebrospinal fluid haemorrhage with cytological examination8 was also done. Head circumference was watched during treatment.
Intravenous fluids
Intravenous fluids given were 10 % glucose, generally with sodium-bicarbonate on day 1-2 (6 mmol/100 ml 10 % glucose). Thereafter sodium, potassium, calcium, chloride, and 20% human albumin (AB Kabi, Sweden) were added according to fluid and electrolyte balance. The fluid amounts were 60-80 ml/kg per 24 hours on days 1-2, 80-100 mI/kg per 24 hours on days 2-3, and 100-120 ml/kg per On day 4 the treatment was tailed off over 4-6 days until the serum concentration was below 125 ,umol/l (3 mg/100 ml) before the baby was taken off the ventilator. In infants receiving diazepam the serum concentration of diazepam and N-desmethyldiazepam was measured before the baby was taken off the ventilator.
Treatment with phenobarbitone was continued beyond the neonatal period, generally for 4 to 6 months, if an infant showed clinical signs of convulsions. In such infants the serum concentration of phenobarbitone was kept between 50 and 80 ,mol/l (1.2 and 1-8 mg/100 ml).
Follow-up examinations. Sono-encephalogram and skull transillumination as well as neurological evaluation were made before discharge from the neonatal unit.
At 5-6, 9-10, and 14-18 months neurodevelopmental examinations were performed in all babies. Ophthalmological examination and audiometric tests (at 10-18 months) were also performed in all. Statistical methods. The x2 test has been used for group comparisons. Results Table 2 . Mortality. As shown in Table 3 the total mortality (at age 0-12 months) was significantly lower in group B (14%) than in group A (50%). In group A 5 infants died in the neonatal period with anoxic Figure. Although the initial dose was equal in all cases the maximum level generally obtained on day 2 or 3 differed widely, as did the disappearance rate after stopping phenobarbitone. Apart from these pharmacokinetic peculiarities of phenobarbitone, we noted that in infants with serum concentrations greater than 225 ,umol/l (5-2 mg/100 ml) there was invariably a decrease of heart rate below 100 per minute as well as decreased beat-to-beat variability (to less than 5) in infants monitored with a cardiorespirograph. In 6 group B infants blood pressure monitoring showed a decrease of mean arterial blood pressure from 40-S50 to 30-35 mmHg within 15 minutes after intravenous phenobarbitone infusion.
Discussion
Several experimental studies have indicated that barbiturate can ameliorate the effects of various types of brain hypoxia or ischaemia even when administered in the phase of resuscitation.9'2 This has led to clinical trials of barbiturate therapy after cardiac arrest in adults and these have given contradictory results.1" [13] [14] [15] In one report a lower rate of mortality and brain damage was found in the offsprings of rhesus monkey mothers treated by barbiturate before birth. '6 In the present study our aim was to evaluate the outcome of phenobarbitone treatment in the neonatal period as protection against brain lesions in severely asphyxiated newborn infants.
There are several possible mechanisms whereby barbiturate may exert a protecting effect12 14 17-22 for example by a sedative effect, by a reduced cerebral metabolic rate of oxygen (CMRo2) known to follow barbiturate administration, by the anticonvulsive effect per se, by prevention of cerebral oedema and reduction of intracranial hypertension, or by a membrane stabilisation effect. The suggested ability of phenobarbitone to inhibit lipid peroxidation23 has recently been disproved. 24 Recent reports indicate that in asphyxiated preterm newborn infants the autoregulation of cerebral blood flow in relation to blood pressure is lost leading to a pressure passive cerebral blood flow.18 25 Consequently there is a considerable risk of cerebral haemorrhage due to sudden rise in blood pressure often occurring during infant care (for example, at suctioning, handling, feeding, etc.) or during seizures. (In our study 2 (Figure) . Repeated measurements of serum levels must be done during treatment, and heart rate and blood pressure should be monitored continuously.
Brain swelling is common in asphyxiated newborn infants, and was found in 3 Owing to the fact that we had few patients and were not able to achieve a double-blind design, evaluation of our study should be cautious. However, this brain-orientated intensive care regimen including phenobarbitone protection seemed to improve the outlook for this group of patients in whom the prognosis would otherwise have been bad. Whether this regimen can be used in severely asphyxiated low birthweight infants cannot be decided without further clinical trials. Finally, we want to stress that the resources of a neonatal intensive care unit with experience in assisted ventilation and blood pressure monitoring is necessary for this kind of treatment until further experience is gained. 
